Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Drug Profile

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Alternative Names: Arcalyst; IL-1 Trap; IL-1 Trap - Regeneron; Interleukin-1 Trap - Regeneron; KPL 914; RGN 303

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Boston University; Charite - Universitatsmedizin Berlin; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes
  • Phase II Cardiovascular disorders; Urticaria
  • Phase I/II Systemic scleroderma
  • Discontinued Anaemia; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis

Most Recent Events

  • 06 Aug 2018 Kiniksa Pharmaceuticals plans a pivotal phase III trial for Cardiovascular disorders (recurrent pericarditis) in 2H 2018 (Kiniksa Pharmaceuticals pipeline, May 2018)
  • 24 Jun 2018 Biomarkers information updated
  • 01 May 2018 Regeneron Pharmaceuticals and Charite University completes a phase II trial in Urticaria (Treatment-experienced) in Germany (SC) (NCT02171416)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top